Fiche personne


Directeur général du Centre George-François Leclerc

Territoire

Bourgogne

Statut

Hospitalo-Universitaire

Projets


Publications


Eligibility for Adjuvant Cyclin-Dependent Kinase 4/6 Inhibitors in Endocrine Receptor-Positive and HER2-Negative Early Breast Cancer by Age and Type of Surgery.

Houvenaeghel G, Classe JM, Chauvet MP, Colombo PE, Jouve E, Reyal F, Daraï E, Rouzier R, Faure-Virelizier C, Gimbergues P, Coutant C, Mazouni C, Azuar AS, Martino M, Bouteille C, Cohen M, de Nonneville A

Cancers (Basel). 2024 09 27;16(19):

Real-world prevalence, treatment and survival of "high risk" early breast cancer, with mandatory testing of gBRCA1/2 mutation according to the OlympiA trial inclusion criteria: Data from a population-based registry.

Ladoire S, Mamguem Kamga A, Galland L, Desmoulins I, Mayeur D, Kaderbhai C, Ilie SM, Hennequin A, Jankowski C, Albuisson J, Nambot S, Coutant C, Arnould L, Reda M, Truntzer C, Dabakuyo S

Breast. 2024 08 28;78:103789

Respective contribution of baseline clinical data, tumour metabolism and tumour blood-flow in predicting pCR after neoadjuvant chemotherapy in HER2 and Triple Negative breast cancer.

Payan N, Presles B, Coutant C, Desmoulins I, Ladoire S, Beltjens F, Brunotte F, Vrigneaud JM, Cochet A

EJNMMI Res. 2024 07 4;14(1):60

Voir plus